Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
xilonix + onivyde + 5-fluorouracil
- Development stage
- Unknown
- Lead developer
- XBiotech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
This is a combination regimen consisting of Xilonix, Onivyde (irinotecan liposome injection), and 5-fluorouracil (5-FU), sometimes with leucovorin. **Xilonix** is a monoclonal antibody that acts as an interleukin-1 alpha antagonist, targeting inflammatory pathways involved in cancer progression. **Onivyde** is a nanoliposomal formulation of irinotecan, a topoisomerase I inhibitor that interferes with DNA replication in cancer cells. **5-Fluorouracil** is an antimetabolite chemotherapeutic agent that inhibits thymidylate synthase, disrupting DNA synthesis and cell division. This combination has been studied for the treatment of advanced or metastatic pancreatic adenocarcinoma, particularly after progression following gemcitabine-based therapy[2][5]. The regimen aims to leverage complementary mechanisms—immune modulation by Xilonix and cytotoxic effects from Onivyde and 5-FU—to improve outcomes in difficult-to-treat cancers.
- Other names
- irinotecan liposome injection5-FU
02
Targets
IL1A (Interleukin 1 alpha)TS (Thymidylate synthase)TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on xilonix + onivyde + 5-fluorouracil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on xilonix + onivyde + 5-fluorouracil.